Tarsons Products Limited (TARSONS) AI Stock Analysis

• Market Cap: ₹17.11B
• Dividend Yield: 0.64%
• Average Volume (3M): 23.88K
• Price to Earnings (P/E): 61.3
• Beta (1Y): 0.74
• Revenue Growth: 25.22%
• EPS Growth: -25.70%
• Country: IN
• Employees: 823
• Sector: Consumer Goods
• Sector Strength: N/A
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.30
• Shares Outstanding: 53,206,280
• 10 Day Avg. Volume: 39,063
• 30 Day Avg. Volume: 23,883
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹399.00
• Price Target Upside: 25.85% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 59 Neutral
• Price Target: ₹399.00 ▲(25.85% Upside)

The overall score reflects robust financial performance with strong revenue growth but hindered by profitability and free cash flow challenges. Technical indicators suggest a neutral trend, while the high valuation raises concerns about potential overvaluation.

Tarsons Products Limited Business Overview & Revenue Model

Company Description

Tarsons Products Limited (TARSONS) is a prominent Indian company engaged in the manufacturing and distribution of laboratory plasticware. The company operates primarily in the life sciences and healthcare sectors, providing a wide range of laboratory products, including plastic consumables, instruments, and benchtop equipment. Tarsons is known for its high-quality products that cater to scientific research and industrial applications, serving clients across domestic and international markets.

How the Company Makes Money

Tarsons Products Limited generates revenue primarily through the sale of its laboratory plasticware products. The company's key revenue streams include the domestic and international sales of plastic consumables, instruments, and benchtop equipment. Tarsons has established a robust distribution network that facilitates the sale of its products to research institutions, healthcare facilities, and industrial clients. The company's earnings are significantly influenced by its ability to maintain high product quality, expand its product portfolio, and strengthen its market presence through partnerships and collaborations with distributors and research institutions. Additionally, Tarsons invests in research and development to innovate and introduce new products, which can lead to increased sales and profitability.

Tarsons Products Limited Financial Statement Overview

Summary

Tarsons Products Limited demonstrates strong revenue growth and operational efficiency, with a moderate leverage and a healthy equity base. However, challenges in profitability and free cash flow generation need to be addressed to ensure long-term liquidity.

Income Statement

Tarsons Products Limited shows robust revenue growth and improving profitability. The revenue growth rate from 2024 to 2025 was approximately 32.4%, indicating strong business expansion. The gross profit margin in 2025 was about 34.4%, and the net profit margin was 7.6%, which, while positive, suggests room for improvement in cost management. The EBIT margin was 12.3%, and the EBITDA margin was 32.3%, reflecting good operational efficiency. However, the decline in net income from previous years signals some challenges.

Balance Sheet

The company's balance sheet indicates a solid financial structure with a debt-to-equity ratio of 0.54, suggesting moderate leverage. The return on equity for 2025 was 4.7%, which is relatively low, pointing to potential inefficiencies in generating returns for shareholders. The equity ratio of 58.4% indicates a healthy level of financial stability, with a strong equity base.

Cash Flow

Cash flow statements reveal challenges in free cash flow generation, with a negative free cash flow for 2025. The operating cash flow to net income ratio was 3.2, indicating strong cash generation relative to net income. However, the free cash flow to net income ratio was negative, highlighting the need for better capital expenditure management. The company's free cash flow growth rate has been negative over the past year, suggesting potential liquidity concerns.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.85B	3.92B	2.96B	2.83B	2.99B	2.28B
Gross Profit	2.34B	1.35B	2.02B	2.18B	2.19B	1.54B
EBITDA	1.20B	1.27B	1.11B	1.42B	1.61B	1.09B
Net Income	298.82M	297.70M	426.40M	807.14M	1.01B	688.70M
Balance Sheet
Total Assets	0.00	10.80B	9.72B	7.26B	5.44B	2.96B
Cash, Cash Equivalents and Short-Term Investments	363.58M	256.52M	226.11M	600.23M	774.42M	23.32M
Total Debt	0.00	3.39B	2.69B	1.11B	216.65M	335.01M
Total Liabilities	-6.14B	4.50B	3.59B	1.56B	543.96M	516.12M
Stockholders Equity	6.14B	6.30B	6.13B	5.69B	4.90B	2.44B
Cash Flow
Free Cash Flow	0.00	-550.87M	-816.28M	-1.14B	-485.02M	38.33M
Operating Cash Flow	0.00	966.20M	1.03B	755.99M	834.67M	681.55M
Investing Cash Flow	0.00	-1.47B	-2.85B	-1.79B	-1.38B	-639.11M
Financing Cash Flow	0.00	578.12M	1.36B	845.61M	1.30B	-272.23M

Tarsons Products Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 317.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TARSONS, the sentiment is Negative. The current price of 317.05 is below the 20-day moving average (MA) of 340.26, below the 50-day MA of 365.17, and below the 200-day MA of 371.42, indicating a bearish trend. The MACD of -15.14 indicates Positive momentum. The RSI at 29.93 is Positive, neither overbought nor oversold. The STOCH value of 22.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TARSONS.

Tarsons Products Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRMOVER	74 Outperform	₹22.13B	35.90		―	-4.20%	0.92%
HUHTAMAKI	69 Neutral	₹17.43B	23.65		0.93%	-0.87%	-82.44%
STOVEKRAFT	64 Neutral	₹21.17B	51.92		0.39%	6.84%	19.29%
ICEMAKE	60 Neutral	₹11.64B	64.19		0.27%	31.56%	-26.94%
TARSONS	59 Neutral	₹17.11B	61.26		0.64%	25.22%	-25.70%
Sector *	57 Neutral	$3.34B	8.35	-34.32%	2.94%	-25.56%	-353.61%
HIL	―	₹14.11B	79.56		1.60%	―	―